Navigation Links
Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
Date:10/4/2011

l facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's GnRH program include, but are not limited to, risk that elagolix Phase III clinical trials will be delayed or not successfully initiated; risk that elagolix Phase III clinical trials will fail to demonstrate that elagolix is safe and effective for the treatment of endometriosis; risk associated with the Company's dependence on corporate collaborators for clinical development, commercial manufacturing and marketing and sales activities. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2010 and report on Form 10-Q for the quarter ended June 30, 2011. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Neurocrine Biosciences Presents Elagolix Data
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
8. Neurocrine Biosciences Reports Third Quarter 2009 Results
9. Neurocrine Advances VMAT2 Inhibitor Program
10. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Neurocrine Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015 NorthStar Anesthesia , one ... it has been selected by Mercy, based in ... four of their hospitals:  Mercy St. Vincent  Medical Center and ... , Mercy St. Charles  Hospital in Oregon ... Tiffin . "As we looked to ...
(Date:8/27/2015)... TORONTO , Aug. 27, 2015 /PRNewswire/ ... announced the issuance of a white paper on the ... spray product.  The white paper was presented to the ... by Dr. James H. Anderson, Jr. , MD, ... be viewed online on the Generex website. ...
(Date:8/27/2015)...  BioElectronics Corporation (OTC Pink: BIEL), the maker of ... featuring the use of ActiPatch®, its novel musculoskeletal pain ... Congress of the European Pain Federation EFIC®, ... The Company will also be exhibiting at the Congress ... , department clinical and experimental rheumatology from the University ...
Breaking Medicine Technology:Four Mercy Hospitals in Northwest Ohio Select NorthStar Anesthesia 2Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2
... BURLINGTON, Mass., Dec. 7, 2010 ... cardiovascular diagnostic imaging technologies, today announced the publication of ... association of stent thrombosis with lipid core plaque as ... is the first and only FDA-approved system to provide ...
... 2010 Cymetrix, a leader in providing healthcare ... announced an alliance with Siemens Healthcare for financial ... partnership, Cymetrix will assist in the transition of ... systems to Siemens Soarian®. Cymetrix,s system conversion solution ...
Cached Medicine Technology:InfraReDx Announces Publication of a Case Report in Circulation Highlighting Novel Clinical Finding with LipiScan™ Coronary Imaging System 2Cymetrix Forms Alliance With Siemens Healthcare for System Conversion Support 2
(Date:8/28/2015)... Beach, FL. (PRWEB) , ... August 28, 2015 ... ... problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach ... believes that it should begin with the employer and employees getting together for ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... patient loyalty at a low cost. Personalized with practice contact information and logos, ... patients. Dental offices can also incorporate Calendars into seasonal mailings, thank you and ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics ... to go deep sea diving. The act of recreational diving exposes the ... these reasons, it is vital that all recreational and professional divers undergo regular ...
(Date:8/28/2015)... ... 28, 2015 , ... Popular review site Top5MillionaireDatingSites.com recently published ... . According to the listings, MillionaireMatch.com bags the top spot while ... spokesperson of Top5MillionaireDatingSites.com said, “This website has been designed to assist ...
(Date:8/28/2015)... ... August 28, 2015 , ... Inc. magazine today ranked PREVENT Life Safety ... the nation’s fastest-growing private companies. The list was unveiled online at Inc.com and is ... the last three years, PREVENT ranks higher on the list than any other company ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... the gold standard for detecting colon cancer. But many patients ... invasive test.// Recently, a fecal occult blood stool test has ... stool. However, the test misses a majority of cancers. The ... say the results are encouraging. ,“A simple, non-invasive test ...
... unknown origin are the eighth leading type of cancers. ... Profiling // may now help identify where tumors first ... about 86-percent accurate in determining a tumor’s origin. ... tumor type. Giving the wrong treatment may slow recovery ...
... change in body position may increase an individual’s chances of ... recent study . ,The research is based on a ... or a transient ischemic attack (TIA), also known as a ... common, occur when blood flow to the brain is reduced. ...
... treatment with the oral drug bosentan (Tracleer) has led ... arterial hypertension ( PAH) // . ,PAH is ... is believed to cause the overproduction of endothelin, which ... obstructed. This chronic obstruction leads to PAH, a condition ...
... shows a diet rich in omega-3 and omega-6 fatty acids may ... Researchers say they studied mice to determine the effects of a ... animals were divided into four groups. The first received a diet ... a diet rich in omega-6 fatty acids along with the drug ...
... According to latest research patients who were treated for ... of vitamin B12 in their blood.// An increasing amount ... B and depression, but the specifics have not been ... relationship of vitamin B12 and the treatment of depression. ...
Cached Medicine News:
Inquire...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Multi-Tier Shaker...
... shake up to 16 of AutoGen's tube units ... This new system is most appropriate for bacterial ... digestion. Now you can further simplify your ... our AutoIncubator 96 and then placing our 6-hole ...
Medicine Products: